trending Market Intelligence /marketintelligence/en/news-insights/trending/tsPVlUmg9rWPMogV0b16HQ2 content esgSubNav
In This List

Report: Valeant considers selling eye surgery biz to Carl Zeiss

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Report: Valeant considers selling eye surgery biz to Carl Zeiss

Valeant Pharmaceuticals International Inc. is in discussions to sell its unit Bausch & Lomb's eye surgery products business to Germany's Carl Zeiss Meditec AG, Bloomberg News reported, citing people familiar with the matter.

The assets could be valued about $2 billion in a potential deal, the sources reportedly said.

Negotiations are ongoing, and no decisions have been made. Other bidders could also step up, according to the report.